Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENHANCE
2020-004287-26Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Feb 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing Magrolimab + azacitidine with Azacitidine + placebo (2 arms). Primary endpoint: Complete remission rate. Started Feb 2021; status: completed.
02
Drugs
magrolimabazacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2020-004287-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004287-26.